| Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance V Papastergiou, SD Georgopoulos, S Karatapanis World Journal of Gastroenterology: WJG 20 (29), 9898, 2014 | 121 | 2014 |
| Hypergastrinemia is associated with increased risk of distal colon adenomas SD Georgopoulos, D Polymeros, K Triantafyllou, C Spiliadi, A Mentis, ... Digestion 74 (1), 42-46, 2006 | 117 | 2006 |
| Treatment of Helicobacter pylori infection: Past, present and future V Papastergiou, SD Georgopoulos, S Karatapanis World journal of gastrointestinal pathophysiology 5 (4), 392, 2014 | 113 | 2014 |
| Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin SD Georgopoulos, SD Ladas, S Karatapanis, A Mentis, C Spiliadi, ... Digestive diseases and sciences 45, 63-67, 2000 | 98 | 2000 |
| Helicobacter pylori infection in spouses of patients with duodenal ulcers and comparison of ribosomal RNA gene patterns. SD Georgopoulos, AF Mentis, CA Spiliadis, LS Tzouvelekis, E Tzelepi, ... Gut 39 (5), 634-638, 1996 | 91 | 1996 |
| Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: A paradigm shift to improved efficacy SD Georgopoulos, V Papastergiou, S Karatapanis Gastroenterology research and practice 2012, 2012 | 88 | 2012 |
| Current options for the treatment of Helicobacter pylori SD Georgopoulos, V Papastergiou, S Karatapanis Expert opinion on pharmacotherapy 14 (2), 211-223, 2013 | 87 | 2013 |
| Clinical Evaluation of a Ten‐Day Regimen with Esomeprazole, Metronidazole, Amoxicillin, and Clarithromycin for the Eradication of Helicobacter pylori in a High … SD Georgopoulos, E Xirouchakis, B Martinez‐Gonzalez, DN Sgouras, ... Helicobacter 18 (6), 459-467, 2013 | 76 | 2013 |
| Effectiveness of two quadruple, tetracycline‐ or clarithromycin‐containing, second‐line, Helicobacter pylori eradication therapies SD Georgopoulos, SD Ladas, S Karatapanis, K Triantafyllou, C Spiliadi, ... Alimentary pharmacology & therapeutics 16 (3), 569-575, 2002 | 76 | 2002 |
| Nonbismuth quadruple “concomitant” therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial S Georgopoulos, V Papastergiou, E Xirouchakis, F Laoudi, P Lisgos, ... Journal of Clinical Gastroenterology 47 (3), 228-232, 2013 | 68 | 2013 |
| Antibiotic resistance prevalence and trends in patients infected with Helicobacter pylori in the period 2013–2020: Results of the European Registry on H. pylori Management (Hp … L Bujanda, OP Nyssen, D Vaira, IM Saracino, G Fiorini, F Lerang, ... Antibiotics 10 (9), 1058, 2021 | 66 | 2021 |
| Helicobacter pylori and colorectal neoplasia: Is there a causal link? V Papastergiou, S Karatapanis, SD Georgopoulos World journal of gastroenterology 22 (2), 649, 2016 | 62 | 2016 |
| Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area SD Georgopoulos, E Xirouchakis, B Martinez-Gonzales, E Zampeli, ... European journal of internal medicine 32, 84-90, 2016 | 59 | 2016 |
| Adverse event profile during the treatment of Helicobacter pylori: a real-world experience of 22,000 patients from the European registry on H. pylori management (Hp-EuReg) OP Nyssen, A Perez-Aisa, B Tepes, M Castro-Fernandez, J Kupcinskas, ... Official journal of the American College of Gastroenterology| ACG 116 (6 …, 2021 | 58 | 2021 |
| Evaluation of a Four‐drug, Three‐antibiotic, Nonbismuth–containing “Concomitant” Therapy as First‐line Helicobacter pylori Eradication Regimen in Greece S Georgopoulos, V Papastergiou, E Xirouchakis, F Laudi, N Papantoniou, ... Helicobacter 17 (1), 49-53, 2012 | 50 | 2012 |
| The use of ERCP in the study of patients with hepatic echinococcosis before and after surgical intervention C Spiliadis, S Georgopoulos, A Dailianas, A Konstantinidis, M Rimikis, ... Gastrointestinal endoscopy 43 (6), 575-579, 1996 | 49 | 1996 |
| A four-probiotics regimen combined with a standard Helicobacter pylori-eradication treatment reduces side effects and increases eradication rates N Viazis, K Argyriou, K Kotzampassi, DK Christodoulou, P Apostolopoulos, ... Nutrients 14 (3), 632, 2022 | 45 | 2022 |
| Screening for gastric premalignant lesions with narrow band imaging, white light and updated Sydney protocol or both? E Xirouchakis, F Laoudi, L Tsartsali, C Spiliadi, SD Georgopoulos Digestive diseases and sciences 58, 1084-1090, 2013 | 42 | 2013 |
| An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection S Georgopoulos, V Papastergiou Expert Opinion on Pharmacotherapy 22 (6), 729-741, 2021 | 41 | 2021 |
| Predictive factors and prevalence of follicular gastritis in adults with peptic ulcer and nonulcer dyspepsia SD Ladas, T Rokkas, S Georgopoulos, P Kitsanta, C Liatsos, ... Digestive diseases and sciences 44, 1156-1160, 1999 | 37 | 1999 |
